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Abstract
Background: C-arm computed tomography (CT) guided intervention is an increasingly applied technique in
transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). The aim of this study was to analyse the
value of parenchymal blood volume (PBV) maps acquired during C-arm CT acquisition, for pre-treatment evaluation
and planning of TACE in HCC patients.
Methods: A total of 64 HCC lesions in 29 patients (median age, 73 years, range, 62–77 years) were included in this
retrospective study. All patients received cross-sectional imaging (MRI or CT) prior to TACE and C-arm CT PBV
measurement acquisition before performing TACE. Results of cross-sectional imaging regarding the number of HCC
lesions and maximum diameter were compared to PBV–maps. Number of lesions and tumour feeding vessels
detected in PBV-maps were compared to conventional angiography. Results of PBV were analysed concerning
different tumour morphologies (pre-treated, encapsulated and diffuse).
Results: Pre-interventional cross-sectional imaging and PBV maps showed an excellent agreement in lesion
diameter (p = 0.88, MD = −0.28 mm) and number of detected lesions (κ = 1.0). Compared to conventional
angiography, PBV maps showed an increased number of detected lesions (κ = 0.77, p = 0.001) and tumour feeding
vessels (κ = 0.71, p < 0.0001). Diffuse HCC lesion revealed a significantly lower PBV compared to encapsulated lesions
(p = 0.0001).
Conclusions: C-arm CT acquired PBV measurements detect HCC tumours with a lesion detectability comparable to
pre-interventional cross-sectional imaging. Furthermore, this technique facilitates TACE, allowing a more precise
localization of HCC lesions and tumour feeding vessels compared to conventional angiography. Additionally,
calculated PBV values enable a real time quantitative assessment of tumour perfusion.
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tomography, Parenchymal blood volume
* Correspondence: gerd.groezinger@med.uni-tuebingen.de
1Department of Radiology, Diagnostic and Interventional Radiology,
Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany
Full list of author information is available at the end of the article
© 2015 Syha et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Syha et al. Cancer Imaging  (2015) 15:22 
DOI 10.1186/s40644-015-0057-x
Background
Hepatocellular carcinoma (HCC) is one of the leading
tumour entities in industrialized countries. Within the
standard of care, transarterial chemoembolization (TACE)
is recommended as the first-line treatment for compen-
sated patients with intermediate-stage [BCLC (Barcelona
classification of liver cancer) stage B]. Furthermore TACE
might be suitable in early stage HCC as bridging to trans-
plantation or adjuvant therapy (BCLC A) [1].
Detection of smaller or less vascularised liver tumours
is reported to be limited using conventional angiography,
especially in liver parenchyma with inhomogeneous per-
fusion such as cirrhotic liver tissue [2–4]. Besides con-
ventional angiography peri-procedural C-arm computed
tomography (CT) is increasingly used during TACE. The
aim of C-arm CT with a flat detector panel as part of an
angiographic suite is to improve the performance of
intraarterial treatments such as TACE or selective
internal radiation therapy [5]. It allows intraprocedural
acquisition of a volume of interest and post-processing
including maximum intensity projections and multipla-
nar reconstructions comparable to conventional CT. C-
arm CT enables acquisition of unenhanced and contrast
enhanced images of liver parenchyma during different
parenchymal phases [5]. Especially regarding TACE, C-
arm CT increases detectability of HCC lesions and
tumour feeding vessels [6]. Additional information is
gained in over 80 % of patients undergoing TACE [7],
and a substantial change of treatment procedure is de-
scribed in up to 30 % of patients [8]. The introduction of
dual phase C-arm CT increases the amount of informa-
tion acquired as different contrast phases facilitate lesion
detectability [9]. Acquisition of unenhanced and contrast
enhanced C-arm CT furthermore enables acquisition of
parenchymal blood volume (PBV) information and al-
lows assessment of three dimensional (3D) cross-
sectional images including native and contrast-enhanced
anatomical as well as perfusion based data after arterial
or venous injection of contrast medium [10]. Its applica-
tion in neurological imaging has been reported [11] to
show benefits as a monitoring tool during the procedure
but also as an important tool during the pre-selection
process of patients.
This is of great interest for intraarterial treatments of
the liver as perfusion based imaging techniques, such as
volume perfusion CT (VPCT), dynamic contrast en-
hanced ultrasound, or dynamic contrast-enhanced MRI
(DCE-MRI), are currently used for peri-interventional
diagnostics [12–15].
First experiences with this technique in the evaluation
of HCC have been published recently [16–18]. The ap-
plied algorithm in our study allows an acquisition of per-
fusion data using new flat detector generation with 16
bit for 4-fold better low contrast resolution, which is of
great interest especially in parenchymal imaging (Artis Q,
Forchheim, Siemens Healthcare). Compared to previous
studies, the detector readout rate has become faster so
that the acquisition time has been slightly shortened to
approximately 2 s allowing improved patient comfort and
avoiding potential motion artefacts.
The aim of this study was to compare PBV-based cross-
sectional images acquired immediately before performing
drug-eluting bead (DEB) TACE to pre-interventional con-
ventional cross-sectional images (MRI, CT) performed for
tumour staging. Furthermore, the feasibility and accuracy
of PBV acquired images by C-arm CT using newly devel-
oped algorithms embedded in a new flat detector gener-
ation should be evaluated and investigated concerning its
potential in the detection of tumour feeding vessels in
comparison to conventional angiography.
Methods
Study population
A total of 29 patients suffering from early or intermedi-
ate stage HCC (median age, 73 years, range, 62–77
years) and undergoing TACE in our institution between
January and November 2014 were included in this retro-
spective study. Indication for TACE was determined by
our local gastrointestinal tumour board consisting of an
experienced radiologist, a surgeon, a hepatologist and a
pathologist. Patients with intermediate stage HCC
(BCLC B) and early stage HCC (BCLC A) were included.
TACE in BCLC A was performed as bridging therapy or
as adjuvant therapy if curative treatment, such as radio-
frequency ablation or surgery, was not possible. Exclu-
sion criteria in this study were determined considering
CIRSE guidelines [19] and included main portal vein
thrombosis, bilirubin level above 2 mg/dl, creatinine
level above 2 mg/dl, poor functional status (ECOG > 2),
extrahepatic tumour spread, and limited liver function
(Child-Pugh stage C, encephalopathy, ascites). All inter-
ventions were performed by the same board certified
interventional radiologist. Underlying causes for the devel-
opment of HCC were Hepatitis-C-virus infection (n = 9),
Hepatitis-B-virus infection (n = 2), alcohol abuse (n = 9),
or other causes (n = 5). In six patients, the underlying
cause for developing HCC was cryptogenic. Detailed
patient information is given in Table 1. Due to the retro-
spective nature of the study informed consent for retro-
spective data evaluation was waived by the local institutional
review board (IRB).
Pre-interventional imaging
All patients underwent cross-sectional imaging (MRI,
n = 10, or CT, n = 19) before TACE (median, 16 days be-
fore TACE, range, 1–25 days), observing the national
guidelines for the assessment of HCC [20]. Multiphase
CT included non-enhanced, arterial (30 s after injection of
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contrast media) and portal venous phase (70 s after injec-
tion of contrast media) and was performed at a 128 row
detector CT (Definition AS+, Siemens, Germany). In gen-
eral, MRI included at least a T2 weighted turbo-spin-echo
sequence as well as an unenhanced and three dynamic
contrast enhanced T1 weighted gradient-echo sequences
acquired at a field strength of 1.5 T (Avanto, Siemens,
Germany). Patients received 0.1 ml gadobutrol per kilo-
gram of body weight (Gadovist 1,0 mmol/ml, Bayer
Healthcare, Germany). Arterial phase was acquired using
bolus tracking.
All HCC lesions were classified concerning morph-
ology in diffuse (n = 31) or encapsulated (n = 33) lesions.
Encapsulated HCC is defined as a predominantly round
lesion with presence of a capsule and remarkable wash-
out in cross-sectional imaging. Diffuse HCC lesions are
defined as predominantly irregular or lobular lesions
without a capsule [21].
CT and MRI evaluation consisted of detection of num-
ber and extent of HCC lesions. All images were assessed
concerning the modified Response Evaluation Criteria in
Solid Tumours (mRECIST) for the presence and extent
of HCC [22]. Maximum cross-sectional diameter of
viable tumour mass was processed, preferably in an ar-
terial phase. Images analysis concerning mRECIST was
performed retrospectively and blinded to evaluation of
angiographic and C-arm CT data sets by the board certi-
fied radiologist.
Conventional angiography and chemoembolization
The arterial system was accessed through the common
right femoral artery. After arterial puncture (19 G nee-
dle), a 4 F sheath (Terumo, Leuven, Belgium) and a 4 F
straight catheter (Terumo, Leuven, Belgium) were intro-
duced. An aortography was performed to assess the
number and origin of hepatic arteries and for detection
of abnormal anatomic blood supply of the liver in cases
receiving first treatment, especially if anatomic blood
supply was not clear from cross-sectional imaging.
Furthermore, potential parasitic tumour supply was ex-
cluded or in case of presence of such a blood supply,
these vessels were occluded by coils, immediately before
performing chemoembolization. Afterwards, a 4 F Cobra
(C2) or sidewinder (SIM1) configured catheter (Cordis,
Bridgewater, New Jersey, USA) was introduced in the celiac
trunk and coeliacography was performed. For selective
catheterization of hepatic arteries, a 2,7 F coaxial micro-
catheter was used (Progreat, Terumo, Leuven, Belgium).
Superselective chemoembolization was performed using
epirubicin-loaded DC Bead particles (100–300 μm, Ter-
umo, Leuven, Belgium). Loaded microspheres were injected
slowly until near stasis was reached. After a time interval of
approximately 10 min, a selective control angiography was
performed. Number of HCC lesion and tumour feeding
vessels were analysed in selective angiogram of the com-
mon hepatic artery (corresponding to catheter positioning
of C-arm CT).
C-arm CT PBV measurement and image processing
All interventions were performed using a robotic angio-
graphic suite (Artis Zeego Q, VE 40 A, Siemens, For-
chheim, Germany). For acquisition of PBV maps, an
unenhanced rotation (mask run) and contrast enhanced
rotations (return and fill run) were acquired (Acquisition
time per rotation 4 s, total examination time 16 s, 90
KV, 200 ° total angle, 0.8° per frame, 248 frames, matrix
616x480 pixel, flat panel pixel size 616 μm, dose
0.36μGy per frame). For the contrast enhanced rotation,
Table 1 Baseline patient characteristics
Data Value
Age (years)







Serum AFP level (ng/mL)
MELD score






> = 5 1
Lesion size (mm) mRECIST
Mean (SD) 32.33 (21.24)







Epirubicin hydrochloride dose (mg)
Median 40
Range 25 to 50
Interval between baseline CT and TACE (d)
Mean (SD) 15.72 (14.01)
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a total of 30 ml diluted contrast media [7,5 ml Ultravist
370 (Bayer Schering, Leverkusen, Germany) and 22,5 ml
saline solution] was injected by an automated power in-
jector (Accutron-HP-D, Medtron, Saarbrücken, Germany)
with a flow rate 3 ml/s. Contrast injection was manually
triggered after mask run, to guarantee a contrast enhanced
acquisition in a steady state of liver perfusion, according
to a previous study on PBV of the liver [16]. As blood
volume refers to the amount of blood which is present at
a given moment, it can be assumed to be constant during
the time of acquisition. This makes the calculation of CBV
from only two measurements possible: a base-line (mask)
acquired before contrast administration and the contrast
distribution (fill) after contrast injection. Acquired data
allowed reconstruction of non-enhanced images, contrast
enhanced images (arterial phase) including tumour feed-
ing vessels, and PBV maps.
Acquired data were sent to a commercially available
workstation (Syngo XWP, Siemens Healthcare) and
reconstructed automatically. The software adopted the
same post-processing workflow as previously described
in the literature [23]. The mask and the fill run were
reconstructed and subtracted. Non-rigid registration al-
gorithm was performed to mitigate the motion between
the two runs. The steady-state arterial input function
value was calculated from an automated histogram ana-
lysis of the vessel tree. A final scaling was then applied
to the dataset to account for the arterial input value. In
the end, a smoothing filter was applied to the images to
reduce pixel noise.
All processed PBV maps were analysed concerning
number and extent of HCC lesions, whereas the number
of tumour feeding vessels was investigated in PBV maps
and arterial phase C-arm CT images. Retrospective
evaluation of number and extent of HCC lesions were
performed blinded to any results of pre-interventional
cross-sectional imaging. Assessment of tumour feeding
vessels were performed within the angiographic session
in C-arm CT acquisition and conventional angiogram by
a board certified interventional radiologist as all detected
vessels were immediately verified by super selective angi-
ography which means at least segmental angiograms ac-
cording to CIRSE guidelines [19].
Statistics
Statistics were performed using the statistical software
Package JMP (SAS, Cary, NC). Median and interquartile
ranges are given for descriptive statistics. The Wilcoxon
signed rank test for non-normal distributed data was
applied to assess the level of significance. A p-value
lower than 0.05 was accepted as a significant difference.
In case of categorical data Cohen’s κ was processed to
evaluate agreement of different methods. In case of
numerical data a Bland-Altman-plot was performed and
mean difference (MD) as well as 95 % confidence inter-
vals (95 % CI) were given. Correlation between different
measurements and methods was calculated using Spear-
man’s correlation coefficient ρ.
Results
Lesion detection in PBV maps and pre-interventional
imaging
PBV-based C-arm CT was feasible in all patients and
provided diagnostic quality in all cases. All HCC typical
lesions (64/64, lesion diameter >10 mm) detected in pre-
interventional imaging have been identified in PBV maps
(κ = 1, p = 1.0) (Fig. 1). 49/64 lesions were detected in
conventional angiography (κ = 0.77, p = 0.001). A total of
90 tumour feeding vessels were detected in PBV maps
and arterial phase C-arm CT compared to 64 vessels in
conventional angiography (κ = 0.71). This represents a
median of 3 (range 2 to 4) tumour feeding vessels
Fig. 1 a Cross-sectional CT imaging (arterial phase) of an encapsulated HCC lesion with central necrosis. b Corresponding real-time PBV map
gained during C-arm CT acquisition reveals an inhomogeneous hypervascularised HCC lesion in liver segment VII
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detected by PBV maps compared to a median of 2
(range 1 to 3) tumour feeding vessels seen in conven-
tional angiography (p < 0.0001) (Fig. 2). All detected ves-
sels were verified by super selective angiography. No
additional tumour feeding vessels were seen in the super
selective approach. Detailed information about number
of tumour feeders and lesions in C-arm CT and corre-
sponding angiogram are summed up in Table 2.
Comparison of maximum cross-sectional diameter of
all lesions in PBV maps and pre-interventional imaging
revealed a maximum diameter of 32.61 (21.44) mm in
PBV maps and 32.33 (21.24) mm in pre-interventional
imaging (p = 0.88, MD = −0.28 mm, 95 % CI = −5.1 to
4.6 mm). Both method showed excellent correlation
(rho = 0.98, p < 0.0001). The Bland-Altman plot is shown
in Fig. 3.
PBV in diffuse, encapsulated HCC lesions and after
previous treatment
Overall, PBV was 18.25 (6.22) ml/100 ml in HCC lesions,
compared to normal liver parenchyma with PBV of 2.89
(1.16) ml/100 ml (p < 0.0001, mean difference −15.36 ml/
100 ml). HCC lesions having received a previous TACE
session revealed no significant difference in PBV as com-
pared to non-treated HCC lesions (p = 0.09), with a ten-
dency towards higher PBV values in non-treated HCC
lesions, revealing a mean PBV of 19.66 (6.88) ml/100 ml
for non-treated lesions, compared to a mean PBV of 17.08
(5.44) ml/100 ml for pre-treated lesions. Concerning liver
parenchyma, there was no significant difference in pre-
treated and firstly treated parenchyma (p = 0.89). Com-
parison between diffuse and encapsulated HCC lesions
revealed a significantly higher PBV in encapsulated le-
sions, 21.22 (6.29) ml/100 ml, compared to diffuse lesions
with a mean PBV of 15.09 (4.35) ml/100 ml (p = 0.0001).
Normal liver tissue showed no significant difference in
PBV between the groups, with a mean PBV for encapsu-
lated HCC group of 3.05 (1.22) ml/100 ml and a mean PBV
for diffuse HCC group of 2.71 (1.09) ml/100 ml (p = 0.23).
PBV and maximum diameter
Comparison of maximum diameter assessed in pre-
interventional imaging and PBV values revealed no cor-
relation regarding all HCC lesions (rho = 0.23). Separate
analysis of diffuse and encapsulated HCC lesions also
showed no correlation between maximum diameter and
PBV for encapsulated HCC lesions (rho = 0.18). How-
ever, in diffuse HCC lesions, a moderate correlation be-
tween PBV values and maximum diameters was seen
(rho = 0.52).
Discussion
This retrospective study investigates the applicability
and the clinical potential and value of PBV maps as well
as non-enhanced and contrast enhanced C-arm CT ac-
quisition in pre-treatment evaluation of TACE in HCC.
Evaluation of the amount and location of HCC lesions
and tumour feeding vessels is of great importance in
treatment planning of TACE. Conventional angiography
allows only a two dimensional approach to tumour vol-
ume and feeding vessels, whereas most pre-interventional
assessments are based on three-dimensional data, e.g.,
MRI and CT acquisitions. C-arm CT provides an exciting
technology for interventional radiology, as it allows 3D
real-time imaging [24].
Virmani et al. investigated the usefulness of C-arm CT
to optimize the catheter positioning during conventional
TACE. Based on C-arm CT assessment, a correction of
catheter positioning was necessary in 7 of 18 patients
[25]. Kakeda et al. showed that C-arm CT added useful
information for catheter positioning in 81 % of the cases
[7]. These results are supported by our study which
showed an advantage in the detection of tumour feeding
vessels for C-arm CT PBV measurement and arterial
phase imaging in comparison to conventional overview
angiography. Furthermore, anatomic location and extent
of smaller or less vascularised HCC lesions was more
easily appreciated using C-arm CT PBV measurement
when compared to conventional overview angiography.
Fig. 2 a Angiographic overview shows a hypervascularised HCC lesion in Segment VII (white line) with multiple tumour feeders (white arrows).
Extent and location of tumour feeders is confusing. The black arrow marks the right hepatic artery. b–d 2D coronar (b, c) and 3D (d) PBV map
reconstructions after C-arm CT acquisition facilitates analysis of location and extent of tumour feeding vessels
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Fifteen supplementary lesions (23 %) were detected
using PBV maps. All supplementary lesions were con-
firmed in pre-interventional cross-sectional imaging.
These results are comparable to a previous study con-
cerning C-arm CT which reported a detection rate of
supplementary lesions of 15 % [8]. In summary, use of
C-arm CT PBV measurement including non-enhanced
and contrast enhanced anatomical images results in a
more appropriate tumour targeting during DEB-TACE.
In addition to anatomic information in terms of
tumour extent and location, C-arm CT PBV measure-
ment provides quantitative real time information about
tumour perfusion and vascularisation.
Previous studies reported on treatment effects of con-
ventional TACE on blood volume (BV) assessed by
VPCT. Lesions reported to have a partial response
showed decreased BV of about 50 % compared to pre-
treatment values [15, 26]. In our study, pre-treated HCC
lesions tended to have lower PBV compared to HCC
lesions which received TACE for the first time. The
reduction of PBV was about 15 %. The difference is
probably based on two facts. Firstly, we have only cross-
sectional data at one time point. The difference might be
more obvious in longitudinal data sets in which pre- and
post-treatment PBV values of the same subject would be
available. Secondly, the time interval between baseline
and follow-up was only four weeks in the reported stud-
ies [15, 26]. The normal time interval between consecu-
tive TACE sessions in our study ranges between 6 and
12 weeks. C-arm CT with additional PBV maps has only
be evaluated in one previous study which focused on
pre-treatment PBV evaluation in comparison to VPCT
[16]. C-arm CT PBV measurement was described as a
feasible method which allows to process hepatic blood
volume comparable to VPCT data. Our study addition-
ally assessed tumour size which has also be reported to
be a relevant parameter in outcome of patients suffering
from HCC [27]. C-arm CT PBV measurement provides
a real time assessment of tumour size comparable to
pre-interventional cross-sectional imaging and seems
Table 2 Detection of HCC lesions and tumour feeding vessels
Feeders Lesions
Overall Median (range) Overall Median (range)
Angiogram 64 2 (1–3) 49 1 (1–2.5)
C-arm CT/PBV maps 90 3 (2–4) 64 2 (1–3)
CSI n.a. n.a. 64 2 (1–3)
Detection of HCC lesions and tumour feeding vessels in C-arm CT/PBV maps
and corresponding angiogram (common hepatic artery) as well as detection in
pre-interventional cross-sectional imaging (CSI)
Fig. 3 Bland-Altman-plot comparing maximum viable tumour diameter detected in pre-interventional cross-sectional imaging and PBV maps
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therefore to be appropriate for assessment of tumour ex-
tent applying mRECIST criteria. The mean PBV value
for HCC lesions and liver parenchyma observed in our
study was 18.25 ml/100 ml vs. 2.89 ml/100 ml, respect-
ively. This was slightly lower compared to previous study
(25.9 ml/100 ml vs. 4.2 ml/100 ml). The higher PBV of
liver parenchyma might be due to the fact that in the
earlier study, mainly Hepatitis-B associated tumours
were included and it is well known that different under-
lying diseases provoke a different grade of liver fibrosis
[28]. The difference in PBV concerning HCC lesions
could be associated with different tumour morphology
(number of diffuse/encapsulated HCC). Furthermore,
the previous study did not include pre-treated HCC
lesions as we did in our study [16]. Both pre-treatment
situations and diffuse HCC seem to be associated with
lower PBV values. Whereas the lower PBV in pre-treated
lesion might underline a therapeutic effect, the lower
PBV values as well as the association between maximum
lesion diameter and PBV values in diffuse lesions could
be related to the different microvessel structure in
expansive growing HCC [29].
In summary, anatomic as well as quantitative informa-
tion gained in PBV maps and non-enhanced as well as
contrast enhanced C-arm CT acquisition could be used
for a further optimization of chemoembolic treatment of
HCC. Miyayama et al. already showed the usefulness of
tumour feeder detection by C-arm CT for an ultraselec-
tive approach in TACE [30].
The main limitation of this study is its retrospective
design. Only a small sample size of 29 patients is investi-
gated in a cross-sectional approach. Further prospective
longitudinal trials have to be performed to analyse po-
tentials of PBV in prediction of outcome and survival.
Another limitation is the use of two different imaging
techniques in pre-interventional assessment. This limita-
tion is due to the retrospective design of the study and
its acquisition in clinical routine. The aim of this study
was to underline that PBV maps generated from unen-
hanced and contrast enhanced C-arm CT data provides
a useful technique in real-time assessment of HCC. A
histological correlation was not possible, as this was a
human in-vivo study.
Conclusion
C-arm CT PBV measurement provides an appropriate
tool for pre-interventional real time assessment of the
location and extent of HCC tumours with a diagnostic
accuracy comparable to pre-interventional conventional
cross-sectional imaging. Compared to simple contrast
enhanced C-arm CT, PBV maps additionally enable a
quantitative assessment of hepatic and tumour blood
volume, which could be of further interest in a real-time
treatment assessment and planning in DEB TACE of
HCC. Furthermore, C-arm CT acquisition in combin-
ation with PBV measurement seems to be superior in lo-
calisation of tumour anatomy and feeding vessels when
compared to conventional overview angiography.
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